Document:

EX-10.28

 Exhibit 10.28 

C  Confidential 

Evaluation Agreement 

THIS AGREEMENT is dated and effective as of the date of signature of the last party to sign the Agreement (the “Effective Date”) and
is entered into between Merck Sharp & Dohme Corp., with an address at One Merck Drive, Whitehouse Station, NJ 08809-0100 (“MERCK”) and MultiVir Inc. with an address at Houston Technology Center, Suite 325, 410 Pierce Street,
Houston, Texas, 77054, USA (“MULTIVIR”) and confirms the terms upon which MERCK will provide certain materials as listed in Attachment 1 (the “Technology”) and certain information related thereto solely for the purpose of
enabling MULTIVIR to evaluate its interest in further business discussions with MERCK regarding commercial use of the Technology (the “Purpose”). 

MERCK and MULTIVIR agree as follows: 

1. Delivery. Within thirty (30) days of the Effective Date, MERCK shall arrange delivery to MULTIVIR of the Technology in a
quantity specified in Attachment 1 to conduct the evaluation activities described in Attachment 2 (the “Evaluation”). 
 2.
License Grant. MERCK hereby grants to MULTIVIR a non-exclusive, non-sublicensable license to use the Technology solely for research purposes for the Evaluation. 

3. Term. The Term of the Evaluation shall commence on the Effective Date shall continue for a period of six (6) months (“the
Evaluation Period”), unless earlier terminated pursuant to Paragraph 12. The Evaluation Period may be extended by mutual written agreement of the parties unless earlier terminated pursuant to Paragraph 12. 

4. Mutual Benefit. Each party agrees that it is performing its obligations under this agreement in consideration for the agreement of
the other party to perform such party’s obligations. Each party is solely responsible for all of its own costs and expenses associated with the Evaluation. 

5. License Agreements. Not later than thirty (30) days after the expiration of the Term, unless this Agreement is otherwise
extended by mutual written agreement of the parties, MULTIVIR will notify Merck as to whether MULTIVIR is interested in entering into a licensing and commercialization agreement with respect to the Technology; provided, however, that nothing in this
Agreement shall obligate either party to enter into any extension of this Agreement or any additional agreement or agreements related to the Technology. 

6. Ownership and Use of Evaluation Results. MULTIVIR shall provide a written report in English of the results of and data relating to
the Evaluation (the “Evaluation Results”) to Merck at the end of the Term. Any and all Evaluation Results hereunder shall be the sole and exclusive property and confidential information of MERCK. MULTIVIR shall provide to MERCK copies of
all documentation and data relating to the Evaluation or shall permit MERCK to inspect and copy such documentation and data. MERCK hereby grants to MULTIVIR a non-exclusive, nontransferable, royalty free license to use the Evaluation Results solely
for the Purpose, and not for any other purpose. 

 C  Confidential 
  

7. Liabilty. 
 (a) MERCK
assumes no responsibility, nor liability, for the nature, conduct or results of any research, testing or other work performed by MULTIVIR hereunder. 

(b) MULTIVIR UNDERSTANDS THAT THE TECHNOLOGY IS SUPPLIED “AS IS” AND IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED INCLUIDING THAT THE USE OF THE TECHNOLOGY OR EVALUATION RESULTS WILL NOT INFRINGE ANY PATENT OF OTHER PROPRIETARY RIGHT OF ANY THIRD PARTY. MERCK WILL NOT BE LIABLE TO MULTIVIR FOR ANY
LOSS, CLAIM, OR DEMAND MADE BY MULTIVIR OR MADE AGAINST MULTIVIR BY ANY THIRD PARTY DUE TO USE OF THE TECHNOLOGY OR EVALUATION RESULTS. MULTIVIR ACKNOWLEDGES THAT THE TECHNOLOGY IS EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN HAZARDOUS
CHARACTERISTICS, THAT IT IS AWARE OF THE RISKS OF WORKING WITH EXPERIMENTAL MATERIALS AND THAT IT WILL STRICTLY ADHERE TO PROPER LABORATORY PROCEDURES FOR HANDLING BIOLOGICAL SUBSTANCES WITH UNKNOWN HAZARDS. THE TECHNOLOGY WILL NOT BE USED IN
HUMANS. 
 (c) MERCK UNDERSTANDS THAT THE EVALUATION RESULTS ARE SUPPLIED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. 
 8. Use of Technology. 

(a) MULTIVIR agrees that (i) MULTIVIR will use the Technology solely for the performance of the Evaluation and shall not use the
Technology for any other purpose, and (ii) MULTIVIR shall not cause the Technology or any derivatives, analogs, modifications or components thereof to be transferred, delivered or disclosed to any Third Party without the advance written consent
of Merck. 
 (b) MULTIVIR acknowledges that MERCK’s corporate policy requires that MERCK’s business must be conducted within the
letter and spirit of the law. By signing this Agreement, MULTIVIR agrees to conduct the Evaluation contemplated herein in a manner which is consistent with both law and good business ethics. MULTIVIR shall conduct the in accordance with all
applicable laws, rules and regulations, including, without limitation, all current governmental regulatory requirements and guidelines including without limitation, current NIH guidelines. 

(c) MULTIVIR hereby certifies that it will not and has not employed or otherwise used in any capacity the services of any person debarred
under Section 21 USC 335a in performing any services hereunder. MULTIVIR shall notify MERCK in writing immediately if any such debarment occurs or comes to its attention, and shall, with respect to any person or entity so debarred promptly
remove such person or entity from performing any service, function or capacity related to the Evaluation. MERCK shall have the right, in its sole discretion, to terminate this Agreement immediately in the event of any such debarment. 

  
 2 

 C  Confidential 
  

9. Inventions. It is recognized and understood that the existing and/or already conceived inventions, discoveries and technologies of
MERCK and MULTIVIR are their separate property and are not affected by this Agreement. Any and all discoveries and/or inventions of MULTIVIR, whether or not patentable, resulting from MULTIVIR’s evaluation of the Technology hereunder shall be
the sole and exclusive property of MERCK. MULTIVIR agrees to execute any and all documents deemed necessary or appropriate by MERCK to memorialize the transfer of ownership of all right, title and interest in such discoveries and/or inventions to
MERCK (or MERCK’s affiliate, at MERCK’s direction) throughout the world. 
 10. Confidentiality. 

(a) All information disclosed by MERCK to MULTIVIR, and the Evaluation Results disclosed by MULTIVIR to MERCK under this Agreement shall be
the confidential information of MERCK, shall be maintained in secrecy by MULTIVIR, and shall only be used by MULTIVIR solely for the Purpose set forth herein. MULTIVIR will use reasonable diligence to prevent disclosure, except (i) to its
personnel necessary for the, Evaluation who are bound by obligations of confidentiality and non-use at least as stringent as those set forth herein. The obligations of confidentiality hereunder shall be limited to a period of seven (7) years
from the date of termination of this Agreement. 
 (b) MULTIVIR shall not have any obligation of confidentiality with respect to any
information that (i) was already in its possession prior to receipt from MERCK or development under the Evaluation, as evidenced by competent proof; or (ii) is in the public domain at the time of its receipt from MERCK or development under
the Evaluation or thereafter enters into the public domain through no fault of MULTIVIR; or (iii) is properly obtained by MULTIVIR from a third party with a valid right to disclose such information and under no confidentiality obligation to
MERCK. Any and all MERCK confidential information, upon request shall be promptly returned to MERCK, except that MULTIVIR may retain one copy of such information in its confidential files, solely for record purposes. 

11. Publicity/Use of Names. No disclosure of the existence of, or the terms of, this Agreement may be made by either party, and no
party shall use the name, trademark, trade name or logo of the other party or its employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the
other party, except as may be required by law. 
 12. Termination. Either party may terminate this Agreement at any time with or
without cause effective immediately upon written notice, and no further use of Technology or MERCK confidential information by MULTIVIR is permitted upon termination. Upon termination or expiration of this Agreement, MULTIVIR shall promptly return
or, at MERCK’s request, destroy (and certify such destruction in writing) all remaining Technology. Paragraphs 5 through and including 16 shall survive termination or expiration of this Agreement. 

  
 3 

 C  Confidential 
  

13. Notices. Any notice required or provided for by the terms of this Agreement shall be in writing, addressed in accordance with this
paragraph, and shall be delivered personally or sent by certified or registered mail, return receipt requested, postage paid or by nationally-recognized express courier services providing evidence of delivery. The effective date of any notice shall
be the date of first receipt by the receiving party. Notices shall be sent to the address/addressee given below or to such other address/addressee as the party to whom notice is to be given may have provided to the other party writing in accordance
with this provision. 
  

			
	(Administrative contact)	    	Business Development & Licensing, MRL
		    	Merck Sharp & Dohme Corp.
		    	WP53B-330
		    	770 Sumneytown Pike
		    	West Point, PA 19486, USA
		    	Attn.: VP, Transactions
		    	LKR#140420
		
	With a copy to:	    	Secretary of the Corporation
		    	Merck Sharp & Dohme Corp.
		    	P.O. Box 100, WS3A-65
		    	One Merck Drive
		    	Whitehouse Station, NJ 08889-0100, USA
		    	LKR#140420
		
	If to MULTIVIR:	    	Houston Technology Center, Suite 325
		    	410 Pierce Street
		    	Houston, TX 77002
		    	Attention: President

 14. Entire Agreement. This Agreement, together with any Attachments attached hereto and
specifically referenced herein, constitutes the entire agreement between the parties with respect to the Evaluation and supersedes and replaces any and all previous arrangements and understandings, whether oral or written, between the parties with
respect to the Evaluation. Any amendment or modification to this Agreement shall be of no effect unless made in a writing signed by an authorized representative of each party. 

15. Governing Law. This Agreement shall be construed in accordance with the laws of the State of New Jersey and the patent laws of the
United States, without reference to provisions of conflicts of laws. 
 16. Counterparts. This Agreement may be signed in any number
of counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument. Signatures for this Agreement may be provided by facsimile transmission or PDF file, which shall be deemed to be original
signatures. 

  
 4 

 C  Confidential 
  

IN WITNESS WHEREOF, MULTIVIR and MERCK have executed this Evaluation Agreement as of the date(s) set forth below. 

 

									
	MERCK SHARP & DOHME CORP.	 		 	MULTIVIR INC.
					
	BY:	 	 /s/ Gary Starling
	 		 	BY:	 	 /s/ Nicholas Puro

					
	DATE:	 	 8/21/2014
	 		 	DATE:	 	 8/8/2014

					
	TITLE:	 	 AVP, Biogics Discovery
	 		 	TITLE:	 	 President and COO

  
 5 

 C  Confidential 
  

ATTACHMENT 1 
 Technology to be
provided to MULTIVIR by MERCK: 
 Two 1-mL vials of frozen HEK293 Master Working Cell Bank 293AB, cell concentration approximately 1 x 10e7 cells/mL

 Ten 2.5-mL vials of frozen Working Virus Bank ACN53 MWVB, infectious titer approximately 3.60 x 10e9 IU/mL 

Copies of sterility and mycoplasma testing results will be provided for each bank. 

MULTIVIR Contact: 
 Dr. Sunil Chada

 schada@multivir.com 

832-419-3785 
 MULTIVIR Shipping Address for
Technology delivered for Evaluation hereunder: 
 Dr. T. Subramanian 

Saint Louis University 
 Institute for Molecular Virology 

DRC room 651 
 1205 Carr Lane 

St. Louis, MO 63104 

  
 6 

 C  Confidential 
  

ATTACHMENT 2 
 Evaluation
Activities: To assess the viability of SCH 58500 Ad-p53 (Reference: U.S. IND #6754), MULTIVIR shall perform the following: 
 Expression of
SCH 58500 Ad-53: 
  

	 	•	 	Use Technology to express SCH 5800 Ad-53 for use in the Assays specified below 

  

	 	•	 	Procedural Ref for determination of viral particle concentration: P.W. Shabram et al, HUMAN GENE THERAPY 8:453-465 (March 1, 1997) 

Assays: 
  

	 	•	 	Adenoviral vector titer (IU/ml) 

  

	 	•	 	Adenoviral vector particle number (vp) concentration 

  

	 	•	 	p53 protein expression: dose-response. Includes adenovirus stability testing 

  

	 	•	 	Inhibition of cell proliferation: dose-response 

 Appendices: 

 

	 	1.	Rapid adenovirus titer assay: Adeno-X rapid titer kit (BD-Bioscience-Clontech) 

  

	 	2.	ATCC cell line ordering information 

  

	 	3.	p53 pan ELISA kit ordering information and procedure instructions 

  

	 	4.	MTT assay kit ordering information and sample procedure instructions 

  
 7 

 C  Confidential 
  

Adenovirus Rapid Titer Protocol 

Purpose: To evaluate the titer (IU/ml) of SCH 58500 Ad-p53. 

Reagents: 
  

	 	•	 	SCH 58500 Ad5-p53 

  

	 	•	 	Adeno-X rapid titer kit (BD-Bioscience-Clontech catalogue #K1653-1 or 632250) 

 Procedure: Follow
manufacturer’s instructions and see attached appendices. 

  
 8 

 C  Confidential 
  

Adenovirus Particle Assay 
 Purpose:
To determine adenovirus particle number in purified virus. It cannot be used to determine particle number in unpurified or partially purified samples. 

Reagents: 
  

	 	•	 	Spectrophotometer capable of ultraviolet wavelengths 260 and 280 

  

	 	•	 	Quartz cuvette 

  

	 	•	 	SDS Buffer (0.2% SDS in PBS; 0.2 μm filtered) 

  

	 	•	 	Water for injection or irrigation (WFI) 

  

	 	•	 	Appropriate tubes, micropipettes and tips 

 Procedure: 

 

	1.	Blank the spectrophotometer at 260 and 280 nm using PBS. 

  

	2.	Mix the virus sample (may be diluted first in PBS) in proportions as follows: 

  

	 	•	 	50 μl virus preparation 

  

	 	•	 	50 μl PBS 

  

	 	•	 	100 μl 0.2% SDS 

  

	3.	Read the OD of the diluted virus sample at 260 and 280 nm. The ratio of 260:280 readings should be close to 1.3 for purified virus. 

  

	4.	Calculate the particle number: 

 OD260
reading x dilution factor x 1.1 x 1012 particles = number of particles per ml of sample. 

Reference: 
 Mittereder N. et al. Evaluation of the
concentration and bioactivity of adenovirus vectors for gene therapy. J Virology 1996;70:7489-7509. 

  
 9 

 C  Confidential 
  

p53 ELISA Protocol 
 Purpose: To
detect the expression of exogenous p53 protein after transduction of a p53null human cell line by SCH 58500 Ad-p53. To evaluate the stability of SCH 58500 Ad-p53 at room temperature pre-dilution
and at 37°C pre-dilution. 
 Reagents: 
  

	 	•	 	Titered adenovirus 

  

	 	•	 	p53null NCI-H1299 non-small cell lung cancer, human cell line (ATCC #CRL-5803) 

  

	 	•	 	p53 pan ELISA kit from Roche Diagnostics 

  

	 	•	 	6-well cell culture plates, sterile 

  

	 	•	 	Cell culture medium: DHGFi5 = Dulbecco’s Modified Eagle Medium, 0.45% glucose, 5% FBS 

  

	 	•	 	DPBS 

  

	 	•	 	0.25% trypsin-EDTA 

  

	 	•	 	Cell lysis buffer = 10 mM Tris-HCl, 10 mM NaH2PO4/NaHPO4 (pH 7.5), 130 mM NaCl, 1% Triton®-X-100, 10 mM NaPPi (sodium pyrophosphate) 

 

	 	•	 	Protease inhibitor cocktail = a mixture of 6 protease inhibitors and EDTA (Cell Signaling catalog # 5871S at http://www.cellsignal.com/product/productDetail.jsp?productId=5871 

 

	 	•	 	96-well microliter plates 

 Procedure: 

 

	 	1.	Day 1: Seed H1299 cells at a density of 5 x 105 cells/well into each well of 6-well plates containing DHGFi5. 

 

	 	2.	Incubate cell culture plates at 37°C and 5% CO2) for 24 hours, until approximately 75% cell confluency. 

 

	 	3.	Day 2: Incubate aliquots of the undiluted Ad vector at 37°C for 5 minutes and for 30 minutes. An undiluted aliquot of the Ad vector will be kept at room temperature before dilution. 

 

	 	4.	Dilute each of the adenovirus test articles pre-incubated in step 3. The adenovirus stock solution should he prepared by dilution with DHGFi5. The concentrations of the Ad stock solutions and the dose range will be
determined after virus titers are available. 

  
 10 

 C  Confidential 
  

 

	 	5.	Carefully remove cell culture medium without detaching the adherent cells in each well. 

  

	 	6.	Pipette 0.5 ml of each Ad dilution or plain medium into each well Each Ad concentration should be tested in triplicate (3 wells in the culture plate). The last 3 wells should receive 0.5 ml of DHGFi5 per well to serve
as a negative control. 

  

	 	7.	Incubate the cell culture plate at 37°C and 5% CO2 for 1 hour. 

  

	 	8.	Add 2 ml of DHGFi5 to each well and continue to incubate the plate at 37°C and 5% CO2 for an additional 23 hours. 

 

	 	9.	Carefully remove cell culture medium without detaching the adherent cells in each well. Then, rinse cells with 2 ml Versene (PBS-EDTA) or PBS. 

 

	 	10.	Add 0.5 ml of a 0.25% solution of trypsin-EDTA to each well. After the cells become non-adherent, add 0.5 ml of DHGFi5 per well to neutralize the trypsin. 

 

	 	11.	Pipette each well of cells into a centrifuge tube and centrifuge gently to pellet the cells. 

  

	 	12.	Remove the supernatent from each tube and gently resuspend each cell pellet in 1 ml DPBS. 

  

	 	13.	Centrifuge gently to pellet the cells and remove the supernatent. The cell pellets may be used immediately or stored at
£ -60°C for up to 1 month. 

  

	 	14.	Lyse each cell pellet using a mixture of cell lysis buffer and protease inhibitor cocktail. 

  

	 	15.	Using a microfuge, centrifuge down the cell debris, then collect the supernatants into clean test tubes for analysis in the p53 pan ELISA assay kit. Follow the manufacturer’s instructions. An overview follows:

  

	 	16.	The sample derived from the negative control cells is diluted 1 in 100 with the Dilution Buffer in the assay kit and an aliquot of this diluted negative control is used to prepare a p53 standard spiked negative control
by the addition of 300 μl of the spiked negative control and 100 μl. of Solution 2f from the assay kit. 

  

	 	17.	A p53 standard curve is derived from Solutions 2a through 2f of the assay kit. 

  

	 	18.	The samples deriving from the test article and the adenovirus-transduced cells are diluted 1 in 1000, 1 in 2000, and 1 in 4000 with the Dilution Buffer. 

 

	 	19.	A 100 μl aliquot of all samples, controls and standards are loaded in triplicate into wells of a 96-well microtiter plate and 100 μl of the Incubation Buffer (Solution 7 of the assay kit) is added to
each well. The plate is covered and incubated at room temperature for 2 hours on an orbital shaker. 

  
 11 

 C  Confidential 
  

 

	 	20.	After this 2 hour period, the Incubation Buffer is removed and the wells washed 5 times with 300 μl of Wash Buffer (Solution 4 of the test kit). 

 

	 	21.	After this, 200 μl of the Substrate Solution (Solution 5 of the test kit) is added to each well and the plate is covered and incubated at room temperature on an orbital shaker for between 10 and 20 minutes.

  

	 	22.	After this period, 50 μl of the Stop Solution (Solution 6 of the test kit) is added to each well and mixed by pipetting. 

  

	 	23.	The intensity of color formed from the Substrate Solution is proportional to the amount of p53 protein present and is determined by a plate reader. The level of p53 protein produced by the cells is read directly off the
standard curve. 

  
 12 

 C  Confidential 
  

Cell Proliferation Assay 
 Purpose:
To determine the dose-response effects of SCH 58500 Ad-p53 on cell proliferation in vitro. 
 Reagents: 

 

	 	•	 	Titered adenovirus 

  

	 	•	 	4 cells lines: MDA-MB-231 breast cancer cell line, human (ATCC #HTB-26); DLD-1 colorectal carcinoma cell line, human (ATCC #CCL-221); DU-145 prostate cancer cell line, human (ATCC #HTB-81); SW-480 colorectal carcinoma
cell line, human (ATCC #CCL-228) 

  

	 	•	 	Cell culture medium = DMEM with 10% FCS at 37 and 5% CO2 

  

	 	•	 	96-well cell culture plate, sterile 

  

	 	•	 	MTT assay kit (any vendor) 

 Procedure: 

 

	 	1.	Day 0: Plate cells at a density of 1.5 x 104 cells/well on a 96-well culture plate. Culture for 4-5 hours at 37°C and 5% CO2, 

  

	 	2.	Dilute adenovirus for a stock solution that can used to generate a dose-response curve: Final Ad in each well at an MOI (IU/cell) of 0, 10, 20, 40, 60. 

 

	 	3.	Add adenovirus vector or vehicle to each well in triplicate and continue to culture at 37°C and 5% CO2 for a total of 3 days (Day 3). 

 

	 	4.	Measure cell proliferation using the MTT assay according to the manufacturer’s instructions. Briefly, add 25 μl of 5 mg/ml MTT vital dye to each well and continue incubation was for 3-4 hours at 37°C and
5% CO2. Then add 100 μl of 10% SDS detergent to each well and incubate overnight. Quantitate the fluorescence in each well using a microtiter plate reader. 

SCH 58500 References: 
  

	 	•	 	Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer
Chemother Pharmacol 1999;44:143-151. 

  

	 	•	 	Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res
1998;4:835-846. 

  
 13EX-10.29

 Exhibit 10.29 

SAINT LOUIS UNIVERSITY 

LABORATORY SERVICES AGREEMENT 

THIS LABORATORY SERVICES AGREEMENT (“Agreement”) is made effective as of December 3, 2012 (“Effective
Date”) by and between VirRx, Inc., having a principal place of business at 1609 Adgers Wharf Drive (“Company”) and Saint Louis University, a Missouri benevolent corporation having its principal place of business located at
221 North Grand Boulevard, St. Louis, Missouri 63103 (“SLU” or “Laboratory”). Company and Laboratory are sometimes referred to herein individually as a “Party” and collectively as the
“Parties.” 
  

	 	1.	Nature of Services. 

 Laboratory will perform services for Company’s research,
preclinical, and/or clinical studies specified in Exhibit A (“Services”). For the avoidance of doubt, neither the payment provided under this Agreement, nor anything else in this Agreement imposes any obligation, express or
implied, to purchase, order, or lease any Company product, or to arrange for or recommend the purchase, order, or lease of any Company product. The Services under this Agreement will be performed personally by Laboratory and may not be assigned to
any other agent of Laboratory without Company’s prior written consent. 
  

	 	2.	Delivery of Services. 

 (a) Laboratory will perform, and warrants that it will perform,
the Services (i) in accordance with any written instructions by Company, the terms of this Agreement and any study protocol or applicable research plan (the “Protocol”) as directed by Company; (ii) to the best of its
ability in a professional manner consistent with industry standards; (iii) in accordance with the standard of care customarily observed with regard to such services in Laboratory’s field of expertise; (iv) in a timely manner; and
(v) in compliance with all applicable laws, rules, guidance and regulations, including without limitation, where applicable, current good clinical or laboratory practices as set forth in either the U.S. Food, Drug and Cosmetics Act, as may be
amended, and regulations promulgated thereunder or equivalent laws, rules and/or regulations in other relevant jurisdictions where Services are performed. 

(b) In the event of an undisputed material error by Laboratory in the performance of any Services hereunder that renders such Services
invalid, Laboratory shall, at Company’s option and notwithstanding other remedies available at law or in equity, shall refund to Company the contract price paid for such Services. 

(c) Laboratory will prepare and maintain complete and accurate records and data for the Services and will maintain such records and data with
respect to the Services, including the raw data and notebooks, for five (5) years (or less upon Company’s written request) after completion of the Services. 

(d) Company’s representatives may visit Laboratory’s facilities at mutually agreeable times and with reasonable frequency during
normal business hours to observe the progress of the Services. Laboratory will assist Company in scheduling such visits. 
 (e) Upon at
least ten (10) business days’ prior written notice from Company’s representative, Laboratory will make available to Company or its representatives during normal business hours data and records that Laboratory compiles in the course of
the Services. During these visits, Company’s representatives may examine the reports containing the results of all quality assurance inspections performed by Laboratory with respect to any Services and to examine the controls and procedures
used by Laboratory in the performance of such quality assurance inspections. 

 (f) Upon reasonable notice and at reasonable times or as required by applicable law or
regulation, Laboratory will permit the U.S. Food and Drug Administration, or any regulatory agency of applicable jurisdiction access to the records maintained pursuant to this Section 2 for purposes of source data verification, auditing or
inspection. 
 (g) Upon Laboratory’s completion of the Services performed under this Agreement, Laboratory will transfer to Company all
data and results in the form of a comprehensive final report or final database (the “Final Report”), which shall include all data, results and conclusions generated by Laboratory during the performance of the Services, along with a
summary of the processes used. Laboratory shall provide Company with one (1) hard copy and (1) one electronic copy of the Final Report. 
  

	 	3.	Materials. 

 (a) Company will provide Laboratory with sufficient amounts of all Company
proprietary materials, or other substances with which to perform the Services, as set forth in Exhibit A (“Materials”), as well as such sufficient and comprehensive data as may be reasonably required by Laboratory concerning
the stability, storage, and safety requirements of the Materials, including a Material Safety Data Sheet as required by applicable law. 

(b) Laboratory will use the Materials only in the performance of the Services as specified in this Agreement. Laboratory shall not, and shall
not permit the use of, either its Materials or any other biological materials treated therewith in human beings, or in any in vivo studies unless specifically included in this Agreement. Laboratory shall not distribute or release Materials to any
person or institution other than those under the direct supervision and responsibility of Laboratory including those consultants or subcontractors engaged by Laboratory in accordance with Section 2(h) above, and shall ensure that no one will be
allowed to take or send Materials to any other location, unless Company gives its prior written permission. Laboratory shall not provide or permit the provision of Materials to any person or institution who has not entered into a written agreement
with Laboratory that permits Laboratory and Company to enforce the restrictions contained in this Agreement against such person or institution. 

(c) Laboratory shall not replicate, modify, formulate, analyze, attempt to determine the structure of, or reverse engineer the Materials or
otherwise treat the Materials in any other fashion, except to the extent specifically required to perform the Services as specified in this Agreement. 

(d) Company retains all right, title and interest in and to the Materials. Nothing in this Agreement shall be construed to grant or imply any
right or license to use, make or sell the Materials or any Company patents or patent applications for any purpose other than as expressly permitted herein. Company shall be free without restriction to distribute the Materials to others and use them
for its own purposes. Unless otherwise instructed in Exhibit A, Laboratory will promptly return to Company or otherwise dispose of any quantities of the Materials remaining after completion of the Services and will certify such disposition in
writing. 
 (e) Upon completion of the Services, any remaining analytical or test samples (other than Materials) provided to or generated by
Laboratory in the course of performing the Services, including without limitation tissue samples, blood, plasma or urine samples, histology samples, or control materials, will be retained by Laboratory at no charge to Company for a period of six
(6) months following the completion of sample analysis. Upon expiration of any retention period, Company must contact Laboratory to determine 

  
 2 

 
whether such samples will be disposed of according to Company’s directions or will be returned to Company, each at Company’s expense. Should Company require retention of such samples or
control materials by Laboratory after the six (6) month retention period and Laboratory determines it is feasible to continue storing such samples or control materials, then Company and Laboratory shall negotiate appropriate rates for such
storage consistent with industry standards. In the event an agreed upon rate cannot be reached, Laboratory shall return such samples or control materials to Company at Company’s expense. Laboratory shall be solely responsible for any waste
material generated by Laboratory in connection with the performance of Services. 
 (f) COMPANY PROVIDES ALL MATERIALS AND CONFIDENTIAL
INFORMATION “AS IS,” WITH NO WARRANTY, EXPRESS, IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT, EXCLUSIVITY, OR FITNESS FOR A PARTICULAR PURPOSE. 

EXCEPT AS OTHEWISE PROVIDED HEREIN, LABORATORY MAKES NO WARRANTIES, EXPRESS, OR IMPLIED, CONCERNING THE RESULTS OF THIS STUDY OR
MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH RESULTS; PROVIDED HOWEVER, THAT THE SERVICES WERE PERFORMED AND THE RESULTS GENERATED IN ACCORDANCE WITH THIS AGREEMENT AND ALL APPLICABLE LAWS, RULES AND REGULATIONS. 

 

	 	4.	Compensation and Reimbursement. 

 (a) If Company agrees to pay for time spent on travel
by the Laboratory on behalf of Company, such travel time will be invoiced to Company at the rate set forth in Exhibit A and in accordance with the Company Travel Guidelines for consultants and vendors in effect at the time of travel and such
travel time shall be approved in writing by Company in advance. 
 (b) Payments by Company to Laboratory shall not exceed the amounts stated
in the aggregate in Exhibit A unless Company has approved such additional costs in writing in advance. 
 (c) Within fifteen
(15) days of the end of each month, Laboratory will submit invoices referencing this Agreement, a description of the Services provided, any fees and expenses relating to the Services performed during the prior month in accordance with this
Agreement and Exhibit A, and if applicable, the purchase order number as provided by Company. Laboratory will submit invoices to Company as set forth in Exhibit A. 

(d) Company will make payments on undisputed invoices within 45 days of receipt of invoice, payable to Saint Louis University (Tax I.D.
Number: 43-0654872) in United States dollars. With reference to this Agreement in care of: 
 Saint Louis University 

Office of Sponsored Programs 

c/o Clinical Trials Office 

3700 West Pine Mall 
 Fusz
Memorial Hall, Room 368 
 St. Louis, MO 63108-3306 

With notification of payment sent to 

Email: clinical-trials-office@slu.edu 

Phone: 314-977-6335 

  
 3 

	 	5.	Confidentiality. 

 (a) “Confidential Information” means confidential or
proprietary information either disclosed in oral, written or other tangible form or otherwise learned by Laboratory under this Agreement that should reasonably be known to be confidential or proprietary to Company, including but not limited to:
information relating to Company’s Materials; research, development, preclinical and clinical programs; Results (as defined below in Section 6), including without limitation, data and results; pharmaceutical or biologic candidates and
products; inventions, works of authorship, trade secrets, processes, conceptions, formulas, patents, patent applications, and licenses; Inventions (as defined in Section 6); business, product, marketing, sales, scientific and technical
strategies, programs and results, including costs and prices; suppliers, manufacturers, customers, market data, personnel, and consultants; and other confidential or proprietary matters related to Company. 

(b) Obligations. Subject to Section 5(c), until seven (7) years after the expiration or termination of this Agreement,
Laboratory: 
 (i) shall not use Confidential Information except for the purpose of performing Services hereunder; 

(ii) will hold Confidential Information in strictest confidence and shall not disclose Confidential Information to others, except for its
employees, agents, consultants or subcontractors who require Confidential Information for the purpose of performing Services and who are subject to binding obligations of confidentiality and restricted use at least as protective as those of this
Agreement; 
 (iii) will protect the confidentiality of Confidential Information using at least the same level of efforts and measures used
to protect its own confidential information, and at least commercially reasonable efforts and measures, including without limitation limiting access to Confidential Information commensurate with performance of the Services and keeping adequate
records of those with access to Confidential Information and of all uses or dispositions of Confidential Information; and 
 (iv) will
notify Company as promptly as practicable upon becoming aware of any unauthorized use or disclosure of Confidential Information by Laboratory or any person or entity performing Services on Laboratory’s behalf. 

(c) Exceptions. Laboratory’s obligations under Section 5(b) shall not apply to any Confidential Information that: 

(i) Laboratory knew prior to learning it from Company or under this Agreement, as demonstrated by written records predating the date it was
learned from Company or under this Agreement; 
 (ii) is now, or becomes in the future, publicly available other than by an act or omission
of Laboratory; 
 (iii) a third party discloses to Laboratory as a matter of right, without any restriction on disclosure, and without any
breach of any direct or indirect obligation of confidentiality to Company, as shown by Laboratory’s written records contemporaneous with such third party disclosure; or 

(iv) Laboratory independently develops without use of or reference to Confidential Information as demonstrated by Laboratory’s
independent written records contemporaneous with such development. 

  
 4 

 (d) Permissible Disclosures. Notwithstanding other provisions of this Agreement,
Laboratory may disclose Confidential Information to the extent and to the persons or entities required under applicable governmental law, rule, regulation, guidance or order, provided that Laboratory (i) first gives prompt written notice of
such disclosure requirement to Company so as to enable Company to seek any limitations on or exemptions from such disclosure requirement and (ii) reasonably cooperates at Company’s request in any such efforts by Company. 

(e) Third Party Information. Laboratory understands that Company has received and in the future will receive from third parties
confidential or proprietary information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of
Laboratory’s association and thereafter, Laboratory will hold Third Party Information identified as such to Laboratory in the strictest confidence and will not disclose or use Third Party Information, except in connection with Laboratory’s
performing Services requested by Company pursuant to this Agreement, or as expressly authorized in writing by an officer of Company. 
 (f)
Return of Confidential Information. Upon either: (i) the completion of Services or termination of this Agreement; or (ii) Company’s request for any reason, Laboratory will (x) immediately cease all use of all Confidential
Information, and (y) promptly, either return to Company, or if instructed by Company, destroy all Confidential Information, including any copies, extracts, summaries, or derivative works thereof, and certify in writing to Company the completion
of such return and/or destruction; provided, however, that Laboratory may retain one copy of Confidential Information in its legal archives solely for the purpose of monitoring its surviving obligations under this Agreement. 

(g) Company Ownership. Company retains all right, title and interest in and to Confidential Information. This Agreement does not give
Laboratory any right or license, by implication or otherwise, to any Confidential Information or any intellectual property or other rights owned by or licensed to Company, by implication or otherwise, except the right to use Confidential Information
solely for performance of the applicable Services. 
 (h) Injunctive Relief. Laboratory acknowledges that any actual or threatened
breach of this Section 5 will cause Company immediate and irreparable harm that cannot be adequately compensated by monetary damages and it therefore agrees that Company shall not be required to demonstrate irreparable harm in order to seek or
obtain injunctive relief for actual or threatened breach of this Agreement. In addition to any injunctive relief, Company may seek any other remedies available to it at law or in equity. 

(i) Laboratory Confidential Information. Notwithstanding the foregoing, Company acknowledges that Laboratory may have certain
pre-existing business processes, prices, procedures, policies, methodologies, systems, computer programs, software, applications, databases, proposals, and other documentation related to Laboratory’s services or business research plans that may
be used in the course of performing the Services and that should reasonably be known by Company to be confidential or proprietary (hereinafter “Laboratory Confidential Information”). Company agrees that such Laboratory Confidential
Information are and shall remain the confidential information of Laboratory. Unless otherwise agreed to by the Parties in writing under this Agreement, Company further agrees that any improvement, alteration, or enhancement made to such Laboratory
Confidential Information during the course of the Services will also be the confidential information of Laboratory, provided that such Laboratory Confidential Information does not reference or incorporate Confidential Information of Company or was a
specific deliverable defined in the Services in Exhibit A. Laboratory Confidential Information will be subject to the same degree of protection by Company as is required of Laboratory to protect Confidential Information, with the same rights,
obligations and exceptions set forth in this Article 5. 

  
 5 

	 	6.	Intellectual Property. 

 (a) Data and Results. Company shall own all right, title
and interest in and to all raw data, results and information: (i) generated under this Agreement; or (ii) in connection with, or as a result of the Services; or (iii) related to Company’s Confidential Information or
Company’s Materials provided under this Agreement, including without limitation the report prepared or database transferred by Laboratory pursuant to Section 2(g) (“Results”). Notwithstanding the foregoing Laboratory may
use such Results of its internal teaching, academic and research purposes. 
 (b) Inventions. Subject to Section 6(c) below,
Laboratory hereby assigns to Company all of Laboratory’s right, title and interest in and to any intellectual property rights arising from inventions, data, or other discoveries, whether patentable or not, that are made, conceived, reduced to
practice, authored or otherwise developed solely or jointly by Laboratory or any of Laboratory’s employees, agents, consultants or subcontractors in whole or in part through use of Company’s Confidential Information or Materials or
directly related to the performance of Services (“Inventions”). Laboratory agrees to notify Company immediately upon learning of any Inventions and to take whatever reasonable steps necessary, at Company’s expense, to perfect,
protect or enforce Company’s right, title and interest in and to such Inventions. Laboratory hereby grants Company an irrevocable power of attorney to execute on Laboratory’s behalf patent and copyright applications or other such documents
required to protect, enforce or perfect Company’s right, title and interest in and to such Inventions, at Company’s expense. The ownership of any discoveries or inventions other than Inventions as defined in this paragraph shall be decided
in accordance with the laws of inventorship of the United States. 
 (c) Laboratory Property. Notwithstanding anything contrary to
this Agreement or Exhibit A, Company agrees that Laboratory possesses or may in the future possess analytical methods and software which have been developed by Laboratory independent of the provision of Services pursuant to this Agreement,
which shall remain the sole and exclusive property of Laboratory (“Laboratory Property”). The Laboratory Property shall include, without limitation, all improvements, modifications, or enhancements to Laboratory Property, even if
developed by Laboratory in the course of performing Services, provided that such improvements, modification or enhancements do not incorporate or reference Confidential Information or Inventions of Company or was a specific deliverable defined in
Exhibit A. Laboratory hereby grants to Company and its affiliates and subsidiaries a non-transferable, non-sublicensable, non-exclusive, worldwide, perpetual, irrevocable, fully-paid, royalty-free license to use Laboratory Property only to the
extent such Laboratory Property represents the only known mechanism for Company to use and exploit the results of the Services for any purpose, including drug development and commercial purposes, except that such license does not permit the whole or
partial inclusion or incorporation of Laboratory Property into any product or service developed by Company for commercial purposes. 
 (d)
Exclusive License and License Option Agreement. Notwithstanding the foregoing or any other provision in this Agreement, nothing in this Agreement is intended to limit, supersede, modify, terminate or otherwise affect any provision of the
Exclusive License and License Option Agreement between the Parties entered into March 01, 2002, and as amended May 15, 2012 (“License Agreement”), or any of the rights granted to SLU thereunder. 

  
 6 

	 	7.	Representation and Warranties. 

 Laboratory represents and warrants to Company that: 

(a) Laboratory has the full right, power and authority to enter into this Agreement and perform its obligations hereunder without the consent
of any third party and without breach of any agreements with or obligations to any third party; 
 (b) to Laboratory’s knowledge,
Company may freely use, practice, reproduce, distribute, make and sell all Inventions and any other advice, data, information, inventions, works of authorship or know-how that Laboratory conveys or provides hereunder, without restriction and without
infringing or misappropriating any third party (e.g., a university or corporation) intellectual property or other rights; 
 (c) Laboratory
will ensure that all right, title and interest in or to Inventions held by Laboratory employees, agents, consultants or subcontractors is assigned promptly to Laboratory; 

(d) Laboratory will not, and will require that its employees, agents, consultants and subcontractors performing Services under this Agreement
will not, transfer, assign or convey, directly or indirectly, any right, title or interest in or to any Inventions to any third party; 

(e) Laboratory has not entered and currently has no intention of entering into any agreement with or obligation to a third party during the
term of this Agreement that would prohibit Laboratory from providing the Services; 
 (f) Laboratory shall not, in the course of performing
Services, use in any capacity the services of any natural person or entity who has been debarred or notified of potential sanction by the FDA or any other regulatory authority of applicable jurisdiction pursuant to the Generic Drug Enforcement Act
of 1992 or any other equivalent or successor statutes, rules or regulations, or other applicable law, whether foreign or domestic. Upon request by Company in connection with any certification Company may make to any regulatory authority, Laboratory
will certify in writing that it has not used the services of any such person or entity in any capacity in performing Services; 
 (g)
Laboratory will not use or disclose any personal health information or personal data received except as required or permitted by law or regulation, or as authorized by Company in writing, or as authorized in the applicable informed consent form
and/or authorization for disclosure of personal health information or personal data. Laboratory agrees to use appropriate safeguards to prevent any unauthorized disclosures by it of such personal health information or personal data. In the event
that Laboratory becomes aware of a breach of this subsection, Laboratory will immediately notify Company in writing; and 
 (h) Laboratory
will comply with (i) the U.S. Health Insurance Portability and Accountability Act, as may be amended (“HIPAA”), with respect to personal health information as defined under HIPAA. Company agrees not to use or disclose a
subject’s personal health information except as required or permitted by law or regulation or as authorized in the applicable informed consent form or authorization. In addition Company agrees to use appropriate safeguards to prevent any
unauthorized disclosures by it of subjects’ personal health information. 
  

	 	8.	Indemnification. 

 Each Party will defend, indemnify and hold harmless the other Party,
its officers, directors, employees, sublicensees and agents (collectively, the “Indemnified Party”) from and against any and all 

  
 7 

 
losses, liabilities, damages, expenses and costs (including reasonable attorneys’ fees) (“Losses”) resulting from third party claims, demands, suits or proceedings (each, a
“Claim”) arising out of the first Party’s (the “Indemnifying Party”) (i) material breach of this Agreement or any applicable law, rule or regulation, (ii) negligence, recklessness or willful
misconduct in the course of activities carried out in connection with this Agreement, including Company’s direct or indirect use of the Results or Laboratory Property for any purpose; or (iii) breach of a warranty contained in this
Agreement by the Indemnifying Party. The Indemnified Party will notify the Indemnifying Party promptly upon learning of a Claim that might give rise to a Loss, and the Indemnifying Party shall have sole control over the defense provided it does so
diligently, in good faith, and using reasonably experienced counsel with expertise in the relevant field. The Indemnified Party will not settle any Claim against it without the Indemnifying Party’s prior written consent, which consent shall not
be unreasonably withheld. The Indemnified Party will reasonably cooperate in such defense and/or settlement at the Indemnifying Party’s request and expense and may participate at its own expense using its own counsel. 

 

	 	9.	Insurance. 

 Laboratory warrants and represents that the Institution has the following
insurance or self-insurance in amounts no less than that specified for each type: Professional liability insurance with combined limits of not less than $1,000,000 per occurrence and $3,000,000 in aggregate. Institution shall also maintain other
insurance policies or a self-insurance program at levels sufficient to meet its liability obligations under this agreement and its legal obligations under Missouri law. Upon Company’s reasonable request, Laboratory will provide Company with
certificates of insurance evidencing such coverage. Company shall maintain insurance or self-insurance in an amount reasonably adequate to cover its obligations hereunder in amounts no less than $1,000,000 per occurrence and $3,000,000 in the annual
aggregate, and shall, upon the reasonable request of Laboratory, forward to Laboratory evidence of insurance or self-insurance. 
  

	 	10.	Term and Termination. 

 (a) The initial term of this Agreement shall commence on the
Effective Date and shall expire upon completion of the Services set forth in this Agreement, unless earlier terminated in accordance with this Section 10. 

(b) Termination of this Agreement Without Cause by Either Party. Either Party may terminate this Agreement at any time upon thirty
(30) days’ written notice to the other Party. 
 (c) Termination of this Agreement by Company. Company may, at any time,
terminate this Agreement for business, financial, technical or regulatory reasons by giving Laboratory prior written notice of such termination. 

(d) Accrued Rights and Obligations; Surviving Provisions. Expiration or termination of this Agreement shall not affect accrued rights
or obligations of the Parties. Sections 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 3(c), 3(d), 3(e), 3(f), 4(d), 5, 6, 7, 8, 9, 10, 11 and 12 shall survive termination or expiration of this Agreement. 

 

	 	11.	Publication. 

 Laboratory shall not disclose, present, disseminate, distribute or produce
any publications with respect to Confidential Information or Inventions without Company’s prior written consent. 

  
 8 

	 	12.	General. 

 (a) Governing Law; Language. This Agreement shall be governed by and
construed in accordance with the laws of the State of Missouri without regard to any conflict of laws provisions, and to the extent applicable, the federal law of the United States. The official text of this Agreement and any exhibits referenced
herein, or any notice given or accounts or statements required by this Agreement shall be in English. In the event of any dispute concerning the construction or meaning of this Agreement, reference shall be made only to this Agreement as written in
English and not to any translation into any other language. 
 (b) Assignment. Any purported assignment or delegation by Laboratory
of this Agreement in whole or in part without the prior written consent of Company shall be void. Company has the unconditional right to assign this Agreement if there is no resulting material change in the scope of the Services. This Agreement
shall be binding upon the Parties, their successors and their permitted assigns. 
 (c) Notices. Any notices given under this
Agreement shall be in writing and shall be deemed given upon personal delivery, facsimile transmission with electronic confirmation of transmission, delivery by internationally- or nationally-recognized bonded courier service, or seven (7) days
after sending by certified or registered mail, postage prepaid and return receipt requested, to the following address or facsimile numbers of the respective Parties or such other address or facsimile number as given by written notice under this
Section 12(c): 
  

			
	Company:	  	 VirRx, Inc
 1609 Adgers Wharf Drive

Chesterfield, MO 63017
 Phone 314-605-8699

		
	Laboratory:	  	 Institute for Molecular Virology
 Saint Louis
University School of Medicine
 E.A. Doisy Research Center, Room 623

Phone: 314-977-8794
 FAX: 314-977-8798

E-mail: chinnag@slu.edu

		
		  	 For Legal/Subject Injury Matters:
 Clinical
Trials Office
 Saint Louis University
 3545 Lafayette Avenue,
2nd Floor, Room 2378
 St. Louis, MO 63104
 Phone:
314-977-6335
 Fax: 314-977-4080

 (d) Amendment. No amendment to or waiver of rights under this Agreement is effective unless in writing
and signed by authorized representatives of the Parties. No modification or amendment to this Agreement shall be effected by or result from the receipt, acceptance, signing or acknowledgement of Laboratory’s purchase orders, quotations,
invoices, shipping documents or other business forms containing terms or conditions in addition to or different from the terms and conditions set forth in this Agreement, and the terms of this Agreement shall supersede any provision in any purchase
order, request for quotation or other document that is in addition to or inconsistent with the terms of this Agreement. 

  
 9 

 (e) Material Non-public Information. Laboratory acknowledges that Company is a publicly
traded company and that, in the course of performance of Services under this Agreement, Laboratory may learn of material, non-public information regarding Company. Laboratory understands that federal and state securities laws prohibit Laboratory
employees from purchasing or selling Company securities while in possession of any such information or from disclosing such information to others. Accordingly, Laboratory employees will not buy or sell Company securities while in possession of any
material, non-public information regarding Company and will not disclose any such information to others. 
 (f) Publicity. Under no
circumstances will either Party use the name of the other Party or any of its personnel for promotion of literature or advertising without the other Party’s prior written approval except to the extent such disclosure is reasonably necessary
for: (i) regulatory filings, including filings with the U.S. Securities and Exchange Commission or the FDA (or any equivalent oversight body in a country other than the United States); (ii) prosecuting or defending litigation; or
(iii) complying with applicable laws, rules, and regulations. Notwithstanding the foregoing, Company may, without Laboratory’s prior consent, identify Laboratory as the entity that is providing Services associated with a study identified
in Exhibit A, as applicable. 
 (g) Entire Agreement. This Agreement, including any attachments referenced herein, sets forth
the complete, final and exclusive agreement between the Parties and supersedes and terminates all prior agreements and understandings between the Parties relating to the subject matter of this Agreement, provided that: (i) the confidentiality
obligations contained in any prior agreement between the Parties and any confidentiality agreement entered into between the Parties shall continue in full force and effect in accordance with its terms; and (ii) the License Agreement shall
continue in full force and effect and this Agreement shall not in any way modify or supersede the terms of the License Agreement. To the extent of a conflict between this Agreement and the License Agreement, the terms of the License Agreement shall
control. This Agreement may be executed in counterparts. If any provision of this Agreement is judicially or administratively determined to be unenforceable, the provision will be reformed to most nearly approximate the Parties’ original
intent, but otherwise this Agreement will continue in full force and effect. If there is any conflict between the terms of Exhibit A and this Agreement, the conflict shall be resolved by interpreting the provisions in the following order of
priority: (1) this Agreement, and (2) the terms of Exhibit A shall govern as to the specific Services in Exhibit A. Exhibit A shall not be deemed to amend the terms of this Agreement unless explicitly stated therein. 

(h) Force Majeure. Neither Party shall be liable for any delay or failure of performance to the extent such delay or failure is caused
by unforeseeable events beyond its reasonable control and that by exercise of due diligence it is unable to prevent any delay or failure of performance under this Agreement; provided, however, that the event is not a result of the asserting
Party’s negligence and that the asserting Party uses and continues to use commercially reasonable efforts to overcome such circumstances. The asserting Party will also use its best efforts to resume performance as quickly as possible. 

(i) Relationship. Laboratory’s relationship with Company will be that of an independent contractor, and nothing in this Agreement
shall be construed to create a partnership, joint venture, or employer-employee relationship. Subject to Section 6(b), neither Party is an agent of the other Party and neither Party is authorized to make any representation, contract, or
commitment on behalf of the other Party. Laboratory will be solely responsible for all taxes and payments required to be filed with or made to any national or local tax authority with respect to Laboratory’s performance of Services and receipt
of fees under this Agreement. 

  
 10 

 The Parties have entered into this Agreement as of the Effective Date by their duly authorized
representatives. 
  

							
	SAINT LOUIS UNIVERSITY	 		 	COMPANY
				
	By:	 	 /s/ Paul Hauptman, M.D.
	 		 	 /s/ Robert E. Sobol

		 	Paul Hauptman, M.D.	 		 	Robert E. Sobol
		 	Asst. Dean for Clinical Translational Research	 		 	CEO, VirRx, Inc.

  

			
	LABORATORY
	Read and Acknowledged:
		
	By:	 	 /s/ Govindaswarny Chinnadurai, M.D.

		 	Govindaswarny Chinnadurai, M.D.

  
 11 

 EXHIBIT A 

Work Plan for Assay of Patient Samples for VRX-007 Phase I Clinical Trial 
  

	A.	Overview 

 The drug to be tested in the clinical trial is named VRX-007. This is a
genetically-modified version of human adenovirus serotype 5 (Ad5). VRX-007 was developed in the laboratory of William S.M. Wold at SLU. VirRx, Inc. was founded by William S.M. Wold and colleagues with a major goal of developing VRX-007 into a commercial anti-cancer drug. 
 In 2007, The Food and Drug Administration approved a Phase
I clinical trial to evaluate the safety and anti-tumor activity of VRX-007 in patients with different types of solid tumors (e.g. head and neck, melanoma, etc). VirRx is the Sponsor of the trial and has an adequate supply of clinical grade (Good
Manufacturing Practice or GMP grade) VRX-007 to conduct the study. 
 The Principal Investigator of the trial is John Nemunaitis, M.D., of
the Mary Crowley Cancer Research Center (Mary Crowley) in Dallas, TX. The trial has been initiated at the Mary Crowley and is expected to continue there as well. 

Three patients have been treated so far in the trial. The remainder of this paragraph and the following three paragraphs outline the protocol
used for these three patients. The patients are screened at the Mary Crowley for suitability (there are various inclusion and exclusion criteria), and a patient consent form is signed by the patients. Among the various pre-treatment assessments,
blood is drawn (day-14, i.e. 14 days pre-treatment) and serum and plasma are prepared from the blood. A urine sample is also obtained at day -14. 

In the actual trial, a single dose of VRX-007 is injected directly into a single tumor in a patient. Blood is drawn at various time points
following the injection of VRX-007, namely 30 minutes, 6 hours, days 2, 4, 8, 15, 22, and 28, and at 12 weeks. (Recall that blood was drawn at day -14). The patient is examined clinically at the time of injection and at each of the time points. The
blood taken at each time point is processed into plasma and serum. The plasma is assayed for the presence of VRX-007, using a laboratory assay called “Tissue Culture Infectious Dose 50%” (TCID50). This assay detects live infectious
VRX-007. The plasma is also assayed for VRX-007 DNA using a Quantitative Polymerase Chain Reaction (qPCR) (also termed RT-PCR) assay. The serum is assayed for the presence of antibodies against VRX-007 that are able to “neutralize”
VRX-007, i.e. prevent VRX-007 from infecting cells growing in culture dishes. These antibodies, called “neutralizing antibodies”, will also detect Ad5. 

In the trial, urine samples are taken from the patients at days 2, 4, 8, 15, 28, and at 12 weeks post-treatment (recall that a urine sample
was taken at day -14 prior to treatment with VRX-007). These urine samples are assayed for VRX-007 by TCID50 assay. 
 At day 8 and 28
post-treatment, a tumor biopsy is taken. If feasible, a biopsy is taken from a nearby tumor nodule that was not injected with VRX-007. These samples are assayed for the presence of VRX-007 by TCID50 assay and for VRX-007 DNA by qPCR assay. 

As mentioned, three patients in the first cohort have been treated with VRX-007. Samples from Patient T-O #002 have been analyzed. (The qPCR
assay was not done for Patient #002). Samples from the second and third patients treated (Patients KVD #003 and REJ #004) are being stored frozen at the Mary Crowley. 

	B.	Work to be Completed by Saint Louis University 

 Prior to initiation of the project, the
protocols will be finalized for the TCID50 assay for viable VRX-007, for the qPCR assay for VRX-007 DNA, and for the neutralizing antibody assays. 

Saint Louis University “Laboratory” team members: Dr. Karoly Toth, a Research Professor in the Department of Molecular
Microbiology and Immunology, and Dr. Wold will develop the assay methods to be used. Dr Toth will train Dr. Chinnadurai and Dr. Subramanian on the methods used in the assays. Neither Dr. Wold nor Dr. Toth will
participate in the actual assays of the patient samples, or in the preparation of the report. 
 The samples from the second (#003) and
third (#004) patient have been collected by the Mary Crowley. As soon as there is approval from SLU, these samples will be sent to Dr. Chinnadurai at SLU, and will be assayed. 

Dr. Chinnadurai will receive the patient samples from the Mary Crowley. The samples will arrive in a frozen state. The samples will be
stored frozen until the assays are conducted. The samples will be coded so that Dr. Chinnadurai does not know the name of the patient or the time point of the samples. He will know whether the sample is plasma, serum, urine, or tumor biopsy.

 The patient samples will be assayed in the laboratory of Dr. G. Chinnadurai, Professor of Molecular Virology in the Institute for
Molecular Virology at SLU. The assays at the laboratory bench will be conducted by Dr. Thirugnana Subramanian, Associate Research Professor in the Institute for Molecular Virology. Dr. Subramanian is a current member of
Dr. Chinnadurai’s laboratory. Dr. Subramanian will work under Dr. Chinnadurai’s supervision in the assay of the patient samples. 

When the samples are to be assayed, they will be thawed by Dr. Subramanian and he will analyze the plasma and urine samples for VRX-007
by TCID50 assay and he will analyze the serum samples for neutralizing antibodies to VRX-007 and Ad5. Also, he will attempt to extract virus from the tumor biopsy samples and assay for VRX-007 by TCID50 assay. 

When these various assays are completed, Drs. Subramanian and Chinnadurai will prepare a report of the results and conclusions of the assays.
The report will be provided to Dr. Robert E. Sobol, CEO of VirRx. Dr. Sobol will provide the report to Dr. John Nemunaitis of the Mary Crowley. 

No further patients are being recruited for the trial at the present time. This is because VirRx has proposed to the FDA that the clinical
trial protocol be revised such that there will be fewer patients per cohort (3 instead of 5), and that the dose escalation proceed more rapidly (e.g. with an increase in dose of VRX-007 of 10-fold between cohorts instead of the current 3-fold).
Also, the Day 22 time point has been eliminated, as has the taking of biopsies. When there is a response from the FDA for this protocol revision, then it is expected that patient recruitment to the trial will begin again. 

Additional Considerations 
 One problem
that may occur is that when the samples arrive at SLU from the Mary Crowley, they are inadvertently allowed to thaw and remain at room temperature (or higher). If so, this fact will be noted and the samples will be assayed according to the standard
protocols. 
 Another problem could be that the assays themselves may not be working. With all the assays, a “positive control” is
included as part of the assay. For the TCID50 assays, the positive control is a known 

 
amount of VRX-007. For the qPCR assays, the positive control will be a known amount of VRX-007 DNA. For the neutralizing antibody assays, the positive control is a known amount of neutralizing
antibodies. If the correct values for the positive controls are not obtained in the assays of the patient samples, then there likely is a technical problem in the assay. If such technical problems arise, Drs. Chinnadurai and Subramanian should be
able to solve the problems because they are extremely experienced virologists. If not, then they will consult with Drs. Wold and Toth in an effort to solve the technical problem. This consultation will focus on the positive controls. No information
will be provided to Drs. Wold and Toth regarding the data on the patients’ samples. 
 Other potential problems, such as equipment
failure, will be addressed by Dr. Chinnadurai. 
 Any problems of a more global nature that cannot be addressed by routine laboratory
practice will be handled by Robert E. Sobol, CEO of VirRx. 
 The samples will be stored in a locked freezer in Dr. Chinnadurai’s
lab. After all the data have been gathered (i.e. all the results obtained), the code on the samples will be partially broken, i.e. Dr. Chinnadurai will be able to determine the patient number and the time point of the sample. This information
will be detailed in the final report. 
 No one in Dr. Chinnadurai’s lab or Dr. Wold’s lab will know the names of the
patients. 
 During the actual analysis at the bench, Dr. Subramanian will make entries into the laboratory notebook. When the analyses
are completed, the laboratory notebook will be given to Dr. Chinnadurai. 
 All records of the sample assays, e.g. laboratory notebooks
and the final report, will be maintained in Dr. Chinnadurai’s office. Dr. Chinnadurai will write the final report. 
 Drs.
Wold and Toth will not have access to the laboratory notebook or the final report maintained by Dr. Chinnadurai. 

 Fees and Expenses. 

For provision of Services under this Agreement, Company will pay Laboratory the following amounts in accordance with the Agreement and on the
following schedule: 
 VirRx Clinical trials 
 Budgets 

 

																							
	10 Studies with TCID50, neutralizing antibody, qPCR	  	 	 	  	7/1/12 - 6/30/13	 
	 	  	FY 13
Salary	 	  	% Effort	 	 	 Salary
	  	Fringe
Rate	 	 	Fringes	 	  	Personnel	 
	 T. Subramanian
	  	 	58,600	  	  	 	15.4	% 	 	9,024	  	 	33.25	% 	 	 	3,000	  	  	 	12,024	  
	 G. Chinnadurai
	  	 	201,900	  	  	 	1	% 	 	2,019	  	 	33.25	% 	 	 	671	  	  	 	2,690	  
		  				  				 	11,043	  				 	 	3,671	  	  	 	14,714	  
					
		  				  				 	 Supplies
	   
	  	 	4,150	  
		  				  				 		  				 				  	  
	  
	 
		  				  				 	 Total general Expense
	    
	  	 	4,150	  
		  				  				 		  				 				  	  
	  
	 
					
		  				  				 	 Direct Cost
	   
	  	 	18,864	  
					
		  				  				 	 Indirect at 12%
	   
	  	 	2,264	  
		  				  				 		  				 				  	  
	  
	 
					
		  				  				 	 Total Cost
	   
	  	 	21,128	  
		  				  				 		  				 				  	  
	  
	 

 Estimated hours of effort: 

 

							
	 	  	Labor for
2 Patients	  	Labor for
10
Patients	 
	 Administration
	  	32	  	 	160	  
	 Preparation
	  	8	  	 	40	  
	 RT - PCR
	  	8	  	 	40	  
	 Neutralizing Ab
	  	8	  	 	40	  
	 TCID50/IC50
	  	8	  	 	40	  
		  	  
	  	  
	  
	 
	 Total
	  	64	  	 	320	  
		  	  
	  	  
	  
	 
			
	 Percent effort for 10 patients =320/2080
	  		  	 	15.4	% 

 Blood 
 Phase 1 or 2 trial of
drug 
 VIRX - blood to Chinna for tests. 

					
	 Total w/o labor
	  	 	4,150	  

  

			
	 Clinical trials sample
 analysis
Chinna
	  	
	Supplies	  	n= 10

  

																																					
	 Item
	 	vendor	 	bulk
price	 	 	amount	 	 	price
ea	 	 	# per
patient	 	 	#/
Assay	 	 	Total for
n
Patients	 	 	Units
needed	 	 	Sum	 	 	 Use

											
	 TCID50 assay
	 		 	 	Total	  	 	 	1,548	  	 				 				 				 				 				 				 	
											
	 DMEM
	 	Sigma	 	 	6.50	  	 	 	1000	  	 	 	0.0065	  	 	 	570	  	 	 	30.0	  	 	 	5,700.0	  	 	 	6	  	 	 	39	  	 	
	 96 well plates
	 	Midwest Sci.	 	 	149.00	  	 	 	96	  	 	 	1.5521	  	 	 	38	  	 	 	2.0	  	 	 	380.0	  	 	 	4	  	 	 	596	  	 	TCID50 titering
	 fetal bovine serum
	 	VWR	 	 	182.80	  	 	 	500	  	 	 	0.3656	  	 	 	19	  	 	 	1.0	  	 	 	190.0	  	 	 	1	  	 	 	183	  	 	TCID50 titering
	 Pipette tips 300ul
	 	Midwest Sci.	 	 	23.00	  	 	 	1000	  	 	 	0.0230	  	 	 	1,900	  	 	 	100.0	  	 	 	19,000.0	  	 	 	19	  	 	 	437	  	 	TCID50 titering
	 Pipette tips 1250ul
	 	Midwest Sci.	 	 	13.00	  	 	 	1000	  	 	 	0.0130	  	 	 	152	  	 	 	8.0	  	 	 	1,520.0	  	 	 	2	  	 	 	26	  	 	TCID50 titering
	 Pipette tips 20ul barrier
	 	Midwest Sci.	 	 	47.00	  	 	 	1000	  	 	 	0.0490	  	 	 	228	  	 	 	8.0	  	 	 	2,280.0	  	 	 	3	  	 	 	141	  	 	TCID50 titering
	 reagent resevoir
	 	Sigma	 	 	126.00	  	 	 	200	  	 	 	0.6300	  	 	 	12	  	 	 	0.04	  	 	 	120.0	  	 	 	1	  	 	 	126	  	 	TCID50 titering
	 Neutralizing antibody assay
	 		 	 	Total	  	 	 	623	  	 				 				 				 				 				 				 	
											
	 DMEM
	 	Sigma	 	 	6.50	  	 	 	1000	  	 	 	0.0065	  	 	 	120	  	 	 	30.0	  	 	 	1,200.0	  	 	 	2	  	 	 	13	  	 	
	 96 well plates
	 	Midwest Sci.	 	 	149.00	  	 	 	96	  	 	 	1.5521	  	 	 	8	  	 	 	2.0	  	 	 	80.0	  	 	 	1	  	 	 	149	  	 	TCID50 titering
	 fetal bovine serum
	 	VWR	 	 	182.80	  	 	 	500	  	 	 	0.3656	  	 	 	4	  	 	 	1.0	  	 	 	40.0	  	 	 	1	  	 	 	183	  	 	TCID50 titering
	 Pipette tips 300ul
	 	Midwest Sci.	 	 	23.00	  	 	 	1000	  	 	 	0.0230	  	 	 	400	  	 	 	100.0	  	 	 	4,000.0	  	 	 	4	  	 	 	92	  	 	TCID50 titering
	 Pipette tips 1250ul
	 	Midwest Sci.	 	 	13.00	  	 	 	1000	  	 	 	0.0130	  	 	 	32	  	 	 	8.0	  	 	 	320.0	  	 	 	1	  	 	 	13	  	 	TCID50 titering
	 Pipette tips 20ul barrier
	 	Midwest Sci.	 	 	47.00	  	 	 	1000	  	 	 	0.0490	  	 	 	32	  	 	 	8.0	  	 	 	320.0	  	 	 	1	  	 	 	47	  	 	TCID50 titering
	 reagent resevoir
	 	Sigma	 	 	126.00	  	 	 	200	  	 	 	0.6300	  	 	 	0	  	 	 	0.04	  	 	 	1.7	  	 	 	1	  	 	 	126	  	 	TCID50 titering
											
	 qPCR for virus
	 		 	 	Total	  	 	 	1,979	  	 				 				 				 				 				 				 	
	 DNeasy Blood & Tissue Kit
	 	Qiagen	 	 	144.00	  	 	 	50	  	 	 	2.8800	  	 	 	19	  	 				 	 	190.0	  	 	 	4	  	 	 	576	  	 	

																																					
											
	 Taqman Probe
	 	IDT	 	 	200.00	  	 	 	1000	  	 	 	0.2000	  	 	 	19	  	 				 	 	190.0	  	 	 	1	  	 	 	200	  	 	
											
	 Primers
	 	IDT	 	 	45.00	  	 	 	1000	  	 	 	0.0450	  	 	 	38	  	 				 	 	380.0	  	 	 	1	  	 	 	45	  	 	
	 TaqMan universal PCR master mix
	 	ABI	 	 	814.00	  	 	 	400	  	 	 	2.0350	  	 	 	19	  	 	 	5.0	  	 	 	190.0	  	 	 	1	  	 	 	814	  	 	
	 96-well qPCR plate
	 	ABI	 	 	103.32	  	 	 	20	  	 	 	5.1660	  	 	 	1	  	 				 	 	10.0	  	 	 	1	  	 	 	103	  	 	
	 adhesive 96-well cover
	 	ABI	 	 	61.75	  	 	 	25	  	 	 	2.4700	  	 	 	1	  	 				 	 	10.0	  	 	 	1	  	 	 	62	  	 	
	 microcentrifuge tubes
	 	Midwest Sci.	 	 	11.00	  	 	 	500	  	 	 	0.0220	  	 	 	133	  	 	 	7.0	  	 	 	1,330.0	  	 	 	3	  	 	 	33	  	 	
	 Filter tip 20 ul tips
	 	Midwest Sci.	 	 	49.00	  	 	 	960.00	  	 	 	0.0510	  	 	 	38	  	 	 	2.0	  	 	 	380.0	  	 	 	1	  	 	 	49	  	 	
	 Filter tip 1 ml tips
	 	Midwest Sci.	 	 	49.00	  	 	 	960.00	  	 	 	0.0510	  	 	 	38	  	 	 	2.0	  	 	 	380.0	  	 	 	1	  	 	 	49	  	 	
	 Filter tip 200 ul tips
	 	Midwest Sci.	 	 	48.00	  	 	 	960.00	  	 	 	0.0500	  	 	 	76	  	 	 	4.0	  	 	 	760.0	  	 	 	1	  	 	 	48	  	 	
		 		 				 				 				 				 				 				 				 	  
	  
	 	 	
									
		 		 				 				 				 				 	 	Total for 10 patients	  	 	 	4,150	  	 	
		 		 				 				 				 				 				 				 				 	  
	  
	 	 	
											
		 		 				 				 				 				 				 				 	 
  
	TCI
 D50
	  
   
	 	 	19	  	 	
		 		 				 				 				 				 				 				 	 
  
	qRT-
 PCR
	  
   
	 	 	19	  	 	
		 		 				 				 				 				 				 				 	 
  
  
	neu
 tr
 ab
	  
   

  
	 	 	4	  	 	

 The amounts set forth herein shall be the maximum compensation payable by Company to Laboratory for Services under this
Agreement. In no instance shall the total compensation payable by Company to Laboratory under this Agreement exceed $30,000. 
 Invoices. In
accordance with the Agreement, Laboratory will submit invoices to Company at the following address: 
 Company: VirRx, Inc., 1609 Adgers
Wharf Drive, Chesterfield, MO 63017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]